0001564590-21-054888 | 10-Q | XBRL Viewer

Liability Related to Sale of Future Royalties - Schedule Represents Allocation of Transaction Consideration on a Relative Fair Value Basis to the Liability and the Common Stock (Detail) - USD ($) $ in Thousands	3 Months Ended
Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Royalty Liability [Abstract]
Liability related to sale of future royalties beginning balance	$ 171,790	$ 168,890	$ 166,068	$ 154,914	$ 148,983	$ 143,276
Interest accretion	2,955	2,871	2,795	5,461	5,912	5,689
Liability related to sale of future royalties ending balance	$ 174,775	$ 171,790	$ 168,890	$ 160,395	$ 154,914	$ 148,983

Label	Element	Value
Increase In Number Of Authorized Shares Reserved For Issuance	cytk_IncreaseInNumberOfAuthorizedSharesReservedForIssuance	4,100,000
Increase In Number Of Authorized Shares Reserved For Issuance	cytk_IncreaseInNumberOfAuthorizedSharesReservedForIssuance	800,000
Increase In Number Of Authorized Shares Reserved For Issuance	cytk_IncreaseInNumberOfAuthorizedSharesReservedForIssuance	1,900,000
Debt Instrument Drawn Amount	cytk_DebtInstrumentDrawnAmount	$ 0
Milestone Payments Received Under Arrangements	cytk_MilestonePaymentsReceivedUnderArrangements	15,000,000.0
Milestone Payments Received Under Arrangements	cytk_MilestonePaymentsReceivedUnderArrangements	2,500,000
Milestone Payments Received Under Arrangements	cytk_MilestonePaymentsReceivedUnderArrangements	5,000,000.0
Interest Receivable And Amortization On Investments	cytk_InterestReceivableAndAmortizationOnInvestments	3,440,000
Interest Receivable And Amortization On Investments	cytk_InterestReceivableAndAmortizationOnInvestments	(402,000)
Sale Of Interest In Future Royalties	cytk_SaleOfInterestInFutureRoyalties	85,000,000.0
Long Term Lease And Other Non Current Liabilities	cytk_LongTermLeaseAndOtherNonCurrentLiabilities	111,788,000
Long Term Lease And Other Non Current Liabilities	cytk_LongTermLeaseAndOtherNonCurrentLiabilities	440,000
Fair Value Of Royalty	cytk_FairValueOfRoyalty	87,000,000
Fair Value Of Royalty	cytk_FairValueOfRoyalty	87,000,000.0
Non Cash Interest Expense Related To Debt	cytk_NonCashInterestExpenseRelatedToDebt	5,250,000
Non Cash Interest Expense Related To Debt	cytk_NonCashInterestExpenseRelatedToDebt	4,949,000
Operating Lease Payments Monthly	cytk_OperatingLeasePaymentsMonthly	$ 500,000
Operating Lease Commencement Period	cytk_OperatingLeaseCommencementPeriod	2021-03
Stock Issue During Period Private Placement Share	cytk_StockIssueDuringPeriodPrivatePlacementShare	2,000,000
Stock Issue During Period Private Placement Share	cytk_StockIssueDuringPeriodPrivatePlacementShare	2,000,000.0
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	cytk_NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	$ 2,955,000
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	cytk_NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	5,461,000
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	cytk_NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	8,621,000
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	cytk_NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	$ 17,062,000
Warrant Expiration Period	cytk_WarrantExpirationPeriod	2030-01
Debt Instrument Number Of Installments	cytk_DebtInstrumentNumberOfInstallments	35
Cash Requirements Term	cytk_CashRequirementsTerm	12 months
Common Stock Purchase Agreement Date	cytk_CommonStockPurchaseAgreementDate	Jul. 14, 2020
Potential Milestone Payments Receivable	cytk_PotentialMilestonePaymentsReceivable	$ 90,000,000.0
Potential Milestone Payments Receivable	cytk_PotentialMilestonePaymentsReceivable	45,000,000.0
Proceeds From Claims Settlements	cytk_ProceedsFromClaimsSettlements	0
Proceeds From Claims Settlements	cytk_ProceedsFromClaimsSettlements	2,151,000
Proceeds From Claims Settlements	cytk_ProceedsFromClaimsSettlements	$ 2,200,000
Number Of Tranche	cytk_NumberOfTranche	2
Tenant Improvement Reimbursements	cytk_TenantImprovementReimbursements	$ 11,100,000
Excess Amount Paid Over Fair Value Of Shares	cytk_ExcessAmountPaidOverFairValueOfShares	13,500,000
Fair Value Of Common Stock	cytk_FairValueOfCommonStock	36,499,000
Fair Value Of Common Stock	cytk_FairValueOfCommonStock	36,500,000
Net Share Settlement	cytk_NetShareSettlement	0
Net Share Settlement	cytk_NetShareSettlement	(418,000)
Net Share Settlement	cytk_NetShareSettlement	0
Net Share Settlement	cytk_NetShareSettlement	0
Net Share Settlement	cytk_NetShareSettlement	(418,000)
Operating Leases Undiscounted Lease Payments	cytk_OperatingLeasesUndiscountedLeasePayments	230,500,000
Convertible Notes Net	cytk_ConvertibleNotesNet	93,885,000
Convertible Notes Net	cytk_ConvertibleNotesNet	89,504,000
Convertible Notes Net	cytk_ConvertibleNotesNet	93,885,000
Drawn Amount Future Exceed Limit	cytk_DrawnAmountFutureExceedLimit	3,000,000.0
Non Cash Lease Expense	cytk_NonCashLeaseExpense	5,407,000
Non Cash Lease Expense	cytk_NonCashLeaseExpense	3,126,000
Finance Lease Future Payments	cytk_FinanceLeaseFuturePayments	3,400,000
Long Term Debt Maturities Repayments Of Principal After Year Four	cytk_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	143,520,000
Stock Issue During Period Private Placement Value	cytk_StockIssueDuringPeriodPrivatePlacementValue	2,000
Stock Issue During Period Private Placement Value	cytk_StockIssueDuringPeriodPrivatePlacementValue	36,435,000
Stock Issue During Period Private Placement Value	cytk_StockIssueDuringPeriodPrivatePlacementValue	0
Stock Issue During Period Private Placement Value	cytk_StockIssueDuringPeriodPrivatePlacementValue	0
Stock Issue During Period Private Placement Value	cytk_StockIssueDuringPeriodPrivatePlacementValue	36,437,000
Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net	cytk_ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet	296,905,000
Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net	cytk_ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet	188,883,000
Accrued Clinical And Preclinical Costs Current	cytk_AccruedClinicalAndPreclinicalCostsCurrent	15,054,000
Accrued Clinical And Preclinical Costs Current	cytk_AccruedClinicalAndPreclinicalCostsCurrent	6,124,000
Potential Milestone Payments And Royalties Receivable	cytk_PotentialMilestonePaymentsAndRoyaltiesReceivable	200,000,000.0
Allocated Transaction Price Of Collaborative Arrangements	cytk_AllocatedTransactionPriceOfCollaborativeArrangements	160,000,000
Proceeds From And Payment Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	cytk_ProceedsFromAndPaymentOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3,569,000
Proceeds From And Payment Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	cytk_ProceedsFromAndPaymentOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3,224,000
Upfront Payment Received	cytk_UpfrontPaymentReceived	25,000,000.0
Payment For Purchase Of Capped Call Options Associated With Convertible Notes	cytk_PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes	13,400,000
Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs	cytk_ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts	133,900,000
Adjustment To Additional Paid In Capital To Section16 B Claim Settlement	cytk_AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement	0
Adjustment To Additional Paid In Capital To Section16 B Claim Settlement	cytk_AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement	2,151,000
Adjustment To Additional Paid In Capital To Section16 B Claim Settlement	cytk_AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement	0
Adjustment To Additional Paid In Capital To Section16 B Claim Settlement	cytk_AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement	0
Adjustment To Additional Paid In Capital To Section16 B Claim Settlement	cytk_AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement	2,151,000
Long Term Debt Maturities Repayments Interest And Final Payment	cytk_LongTermDebtMaturitiesRepaymentsInterestAndFinalPayment	9,325,000
Research And Development Arrangement Contract To Perform For Others Customer Funding	cytk_ResearchAndDevelopmentArrangementContractToPerformForOthersCustomerFunding	35,000,000.0
Payment Of Development Costs For Clinical Trials	cytk_PaymentOfDevelopmentCostsForClinicalTrials	12,000,000
Increase Decrease In Operating Lease Liabilities	cytk_IncreaseDecreaseInOperatingLeaseLiabilities	33,466,000
Increase Decrease In Operating Lease Liabilities	cytk_IncreaseDecreaseInOperatingLeaseLiabilities	(3,457,000)
Debt Instrument Convertible Carrying Amount Of The Liability Component	cytk_DebtInstrumentConvertibleCarryingAmountOfTheLiabilityComponent	84,200,000
Research And Development Arrangement Contract To Perform For Others Customer Commitment	cytk_ResearchAndDevelopmentArrangementContractToPerformForOthersCustomerCommitment	44,200,000
Research And Development Arrangement Contract To Perform For Others Customer Funding And Commitment	cytk_ResearchAndDevelopmentArrangementContractToPerformForOthersCustomerFundingAndCommitment	$ 94,200,000

Liability Related to Sale of Future Royalties - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended	9 Months Ended
	Feb. 28, 2017	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Liability Related to Sale of Future Royalties [Line Items]
Cash payment under royalty agreement	$ 90,000
Non-cash interest expense recognized		$ 3,000	$ 2,800	$ 5,700	$ 5,500		$ 8,600	$ 17,100
Reduction in net loss			$ (2,900)
Changes In Significant Unobservable Inputs						$ 0

Print Document View Excel Document
Notes Details Liability Related to Sale of Future Royalties - Additional Information (Detail) Liability Related to Sale of Future Royalties - Schedule Represents Allocation of Transaction Consideration on a Relative Fair Value Basis to the Liability and the Common Stock (Detail) Uncategorized Uncategorized Items - cytk-10q_20210930_htm.xml All Reports